



2nd May 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544250

The Secretary
National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICNR

Sub.: Outcome of Board Meeting held on Friday, 2nd May 2025

Dear Sir/Madam,

We refer to our letter dated 25th April 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Friday, 2nd May 2025, *inter-alia* considered and approved the Unaudited Financial Results for the quarter ended 31st March 2025.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith a copy of the Unaudited Financial Results for the quarter ended 31st March 2025 approved at this Meeting with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid Financial Results will also be available on the Company's website on <https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results>

The meeting of Board of Directors commenced at 4:15 p.m. and concluded at 6:00 p.m.

Kindly take the above information on record.

Thanking You,

Yours faithfully
For Sanofi Consumer Healthcare India Limited

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

TO THE BOARD OF DIRECTORS

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sanofi Consumer Healthcare India Limited** ("the Company"), for the quarter ended March 31, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), which has been digitally signed by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors at their respective meetings held on May 02, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Attention is drawn to the fact that the figures for the quarter ended December 31, 2024, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended December 31, 2024, and the published year to date figures up to the end of the third quarter of the financial year ended December 31, 2024, which have only been reviewed by us and not subject to audit.

Our conclusion is not modified in respect of this matter.

For KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Firm Registration No. 104607W / W100166

Sai Venkata Ramana Damarla

Partner

Membership. No. 107017

UDIN: 25107017BMLFPT9141

Place: Mumbai

Date: May 02, 2025

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001

TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2025

Particulars	₹ in Million			
	Quarter ended 31.03.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited)	Quarter ended 31.03.2024 (Unaudited)	Year ended 31.12.2024 (Audited)
		Refer note: 5		
1. Revenue from Operations	1,726	1,707	2,216	7,245
2. Other Income	52	50	30	130
3. Total Income (1+2)	1,778	1,757	2,246	7,375
4. Expenses				
(a) Cost of Materials Consumed	189	148	668	1,274
(b) Purchases of stock in trade	335	184	93	421
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	(136)	87	(161)	166
(d) Employee benefits expense	296	276	229	1,027
(e) Finance costs	4	4	-	39
(f) Depreciation and amortisation expense	20	10	9	45
(g) Other expenses	402	391	569	1,651
Total Expenses	1,110	1,100	1,407	4,623
5. Profit before exceptional items and tax (3-4)	668	657	839	2,752
6. Exceptional items (Refer note 4)	-	(29)	-	(284)
7. Profit before tax (5+6)	668	628	839	2,468
8. Tax expense				
Current Tax	170	176	222	696
Deferred Tax	(2)	9	(10)	(38)
9. Profit for the period /year (7-8)	500	443	627	1,810
10. Other comprehensive income (OCI)				
Items that will not be reclassified to the statement of profit and loss				
- Remeasurements of post-employment benefit obligations	-	(19)	-	(19)
- Income Tax impact relating to these items	-	5	-	5
11. Total comprehensive income for the period/year (9+10)	500	429	627	1,796
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	20	230
13. Share capital pending for allotment (Face Value of ₹ 10 per share)	-	-	230	-
14. Other equity	-	-	-	2,500
15. Basic and diluted earnings per share (not annualised) (in ₹)	21.69	19.25	27.22	78.59

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the LODR Regulations review report dated May 02, 2025.

Notes:

1. These unaudited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards ("Ind AS"), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India
2. The statutory auditors have issued a limited review report with an unmodified conclusion on the above unaudited financial results for the quarter ended March 31, 2025. The unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 have been reviewed by the Audit Committee in their meeting held on May 2, 2025 and approved by the Board of Directors of the Company at its meeting held on May 2, 2025
3. Company had during the previous year voluntarily decided to recall Allegra Suspension and Combiflam Suspension as precautionary measure from distributors, hospitals, and retailers on July 19, 2024. Earlier, the Company had recalled Depura Adult and Depura Kids produced by the same manufacturer. The recall of the products is substantially completed from distributors, and it is expected to receive minor returns from retailers within next few months. The Company had taken a decision to temporarily suspend manufacturing of aforesaid products to review and streamline the manufacturing and quality processes at the third-party manufacturer. Depura Adult was relaunched during the current quarter and the endeavor is to bring back the rest of recalled products to the market as soon as possible. Results of quarter ended March 31, 2025 are not comparable with results of quarter ended March 31, 2024 due to voluntary product recall.
4. Exceptional items for the quarter ended December 31, 2024, amounts to ₹ 29 million towards write off of Intangible asset under development (acquired under Scheme of Arrangement) basis internal assessment done by the company of its recoverability. Exceptional items for the year ended December 31, 2024 amounts to ₹ 284 million which includes product recall related cost towards sales return and inventory write off ₹ 108 million, expenses towards listing formalities amounting to ₹ 77 million, demerger expenses amounting to ₹ 70 million and Intangible asset under development written off amounting to ₹ 29 million (acquired under the Scheme of Arrangement).
5. The figures for the quarter ended December 31, 2024 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and the unaudited published year-to-date figures up to September 30, 2024, which were subject to a limited review, being the date of the end of the third quarter of the said financial year
6. The Company has a single business segment namely 'Pharmaceutical Business'.
7. The Company does not have any subsidiary, associates or joint ventures as on March 31, 2025.
8. On April 30, 2025, Sanofi globally closed the sale to CD&R (Clayton, Dubilier & Rice) of a 50% controlling stake of Opella (consumer healthcare division) with Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the LODR Regulations review report dated May 02, 2025.

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu Bakshi
Managing Director
DIN: 08188412

May 02, 2025